
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines has a promising outlook, driven by anticipated growth in partnership revenues from the upcoming launches of zanidatamab and tarlatamab in China, alongside steady contributions from established products like Xgeva and Kyprolis. The company's leading product, Brukinsa, is expected to see approximately $936 million in sales for the second quarter of 2024, bolstered by increased prescription volumes and market recovery in Europe. Additionally, the potential for new drug approaches and a projected ~$650 million increase in sales from lymphoma indications by 2034 further solidify an optimistic financial trajectory for BeOne.
Bears say
BeOne Medicines faces a challenging financial outlook primarily due to the slower-than-expected uptake of its commercial products, particularly Brukinsa, which constitutes over 60% of its revenue. The company is at risk of significant downside if it fails to successfully expand its drug indications and pipeline programs, as evidenced by its setbacks in the solid tumor initiative and other drug candidates. Additionally, perceived geopolitical risks associated with being a Chinese biotechnology firm and ongoing concerns regarding cash burn further complicate its financial stability, especially within a competitive hematology-oncology market.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares